In any case, the presence of platelet factor 4/heparin antibodies is clustered in patients with CSVT (after vaccination) compared with the pre-COVID-19 period, allowing conclusions about the pathophysiology of some but not all affected patients [10]. This evidence concerns the gene PF4 and COVID-19.